Boltz's long-term goal: hypothesis to human-ready molecule without leaving the computer
GabriCorso · x · 2026-11-18
Boltz says its long-term goal is a world where a scientist can go from therapeutic hypothesis to human-ready molecule without leaving their computer. Next-gen models already show substantial quality improvements, and the new funding will expand access for scientists and deepen investment in compute, data and teams.
More from Venture
- SEO consultant pitches 14 journalists a week, calls GEO "BS" — gaganghotra_ · 2026-11-18
- Boltz Lab now a daily tool for pharma scientists; partners include Pfizer, GSK, Takeda, BMS — GabriCorso · 2026-11-18
- Boltz raises $110M Series A for AI biomolecular design, partners with 6 top-20 pharma giants — GabriCorso · 2026-11-18
- Anthropic IPO: $70-78/share, up to ~$1.4T valuation, ~$90B raise with supplier private placement — RihardJarc · 2026-11-18
- Traders Buy Anthropic at $1.8T Valuation on Pre-IPO Perps, Calling It a No-Brainer — adamamcbride · 2026-11-18
- Analyst: Anthropic stake could exceed 20% of Amazon's market cap within weeks — RihardJarc · 2026-11-18